XML 39 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS' EQUITY (DEFICIT) (USD $)
In Thousands, except Share data
Total
Initial Public Offering
Convertible Preferred Stock
Convertible Preferred Stock
Research and Development Funding Arrangement
Common Stock
Common Stock
Initial Public Offering
Additional Paid-in Capital
Additional Paid-in Capital
Initial Public Offering
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning Balance at Dec. 31, 2008 $ (91,166)   $ 89,168   $ 30   $ 6,150   $ (99) $ (97,247)
Beginning Balance (in shares) at Dec. 31, 2008     11,392,057   2,951,406          
Issuance of stock (in shares)       122,451   6,820,000        
Issuance of stock   61,812   1,851   68   61,744    
Conversion of convertible preferred stock to common stock upon initial public offering (in shares)     (11,514,508)   11,514,508          
Conversion of convertible preferred stock to common stock upon initial public offering 91,019   (91,019)   115   90,904      
Conversion of preferred stock warrant liability to equity upon initial public offering 902           902      
Issuance of common stock upon exercise of stock options for cash (in shares)         25,633          
Issuance of common stock upon exercise of stock options for cash 28           28      
Vesting of early-exercised stock options 5           5      
Repurchase of early-exercised stock options (in shares)         (25,970)          
Repurchase of early-exercised stock options                          
Stock-based compensation 1,494           1,494      
Unrealized holding gain on available-for-sale securities 140               140  
Net loss (21,089)                 (21,089)
Comprehensive loss (20,949)                  
Ending Balance at Dec. 31, 2009 43,145       213   161,227   41 (118,336)
Ending Balance (in shares) at Dec. 31, 2009         21,285,577          
Issuance of common stock warrants in connection with Vulcan funding agreement 994           994      
Issuance of common stock to Patobios at $8.30 per share in connection with GPCR technology purchase (in shares)         379,039          
Issuance of common stock to Patobios at $8.30 per share in connection with GPCR technology purchase 3,146       4   3,142      
Issuance of common stock upon exercise of stock options for cash (in shares)         256,220          
Issuance of common stock upon exercise of stock options for cash 299       2   297      
Stock-based compensation 2,178           2,178      
Realized loss on sale of available-for-sale securities (41)               (41)  
Net loss (29,251)                 (29,251)
Comprehensive loss (29,292)                  
Ending Balance at Dec. 31, 2010 20,470       219   167,838     (147,587)
Ending Balance (in shares) at Dec. 31, 2010         21,920,836          
Issuance of common stock upon exercise of stock options for cash (in shares)         509,398          
Issuance of common stock upon exercise of stock options for cash 595       5   590      
Stock-based compensation 1,927           1,927      
Net loss (28,546)                 (28,546)
Ending Balance at Dec. 31, 2011 $ (5,554)       $ 224   $ 170,355     $ (176,133)
Ending Balance (in shares) at Dec. 31, 2011         22,430,234